Education
About Us
Working with TipRanks
Follow Us
Vericel Corp (VCEL)
NASDAQ:VCEL
VCEL Stock Chart & Stats
$37.37
$1.36(2.35%)
At close: 4:00 PM EST
$37.37
$1.36(2.35%)
Day’s Range― - ―
52-Week Range$29.24 - $63.00
Previous CloseN/A
Volume83.17K
Average Volume (3M)845.02K
Market Cap
$1.82B
Enterprise Value$2.13B
Total Cash (Recent Filing)$135.38M
Total Debt (Recent Filing)$98.01M
Price to Earnings (P/E)155.2
Beta1.02
Next Earnings
Feb 26, 2026EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding50,574,024
10 Day Avg. Volume667,266
30 Day Avg. Volume845,017
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)9.19
Price to Sales (P/S)11.31
P/FCF Ratio-461.58
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue8.22
Enterprise Value/Gross Profit11.14
Enterprise Value/Ebitda89.46
Forecast
1Y Price Target
$53.20Price Target Upside42.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Earnings And Growth ProspectsVericel Corporation's MACI and Burn Care segments outperformed, showcasing a rare 19-20%+ growth opportunity with inflecting profitability, contributing to the analyst's recommendation.
Product Expansion And Market PotentialThe MACI Arthro launch, with over 800 surgeons trained, is expected to double MACI procedure volumes by expanding the addressable surgeon and patient base.
Revenue And Profit MarginsVericel Corporation's third-quarter revenue beat expectations due to record MACI revenues and strong burn care performance, achieving 25% adj EBITDA margin and cash generation.
Bears Say
Clinical Trials And Development DelaysA previous Phase III trial for NeoCart failed to meet its primary endpoint, leading to delays and strategic reevaluation for future development.
Regulatory And Revenue ChallengesThe government shutdown puts a pause on the BARDA RFP process, potentially affecting Nexobrid's revenue opportunities.
Strategic And Merger ChallengesThe planned merger between Ocugen's OrthoCellix subsidiary and Carisma Therapeutics was terminated due to insufficient funding, impacting future strategic directions.
Vericel News
VCEL FAQ
What was Vericel Corp’s price range in the past 12 months?
Vericel Corp lowest stock price was $29.24 and its highest was $63.00 in the past 12 months.
What is Vericel Corp’s market cap?
Vericel Corp’s market cap is $1.82B.
When is Vericel Corp’s upcoming earnings report date?
Vericel Corp’s upcoming earnings report date is Feb 26, 2026 which is in 65 days.
How were Vericel Corp’s earnings last quarter?
Vericel Corp released its earnings results on Nov 06, 2025. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of -$0.006 by $0.106.
Is Vericel Corp overvalued?
According to Wall Street analysts Vericel Corp’s price is currently Undervalued.
Does Vericel Corp pay dividends?
Vericel Corp does not currently pay dividends.
What is Vericel Corp’s EPS estimate?
Vericel Corp’s EPS estimate is 0.39.
How many shares outstanding does Vericel Corp have?
Vericel Corp has 50,574,024 shares outstanding.
What happened to Vericel Corp’s price movement after its last earnings report?
Vericel Corp reported an EPS of $0.1 in its last earnings report, beating expectations of -$0.006. Following the earnings report the stock price went up 4.167%.
Which hedge fund is a major shareholder of Vericel Corp?
Currently, no hedge funds are holding shares in VCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.20 (42.36% Upside)
$53.20 (42.36% Upside)
Hedge Fund Trend
Increased
By 272.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $189.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.15%
12-Months-Change
Fundamentals
Return on Equity
4.52%
Trailing 12-Months
Asset Growth
15.60%
Trailing 12-Months
Company Description
Vericel Corp
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
VCEL Company Deck
VCEL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Vericel's strong financial performance with record revenue and profit growth, driven by the success of MACI and the launch of MACI Arthro. However, there are potential challenges related to government processes and reimbursement policies that could impact future growth.View all VCEL earnings summariesVCEL Stock 12 Month Forecast
Average Price Target
$53.20
▲(42.36% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---